T 0883/23 (Liposomal irinotecan drug combination/IPSEN) vom 26.09.2025
- Europäischer Rechtsprechungsidentifikator
- ECLI:EP:BA:2025:T088323.20250926
- Datum der Entscheidung
- 26. September 2025
- Aktenzeichen
- T 0883/23
- Antrag auf Überprüfung von
- -
- Anmeldenummer
- 16758337.6
- Verfahrenssprache
- Englisch
- Verteilung
- An die Kammervorsitzenden verteilt (C)
- Download
- Entscheidung auf Englisch
- Amtsblattfassungen
- Keine AB-Links gefunden
- Weitere Entscheidungen für diese Akte
- -
- Zusammenfassungen für diese Entscheidung
- Zusammenfassung von Article 087(1) EPCZusammenfassung von Article 12(6) RPBA
- Bezeichnung der Anmeldung
- DRUG COMBINATION COMPRISING LIPOSOMAL IRINOTECAN, OXALIPLATIN, 5-FLUOROURACIL AND LEUCOVORIN FOR TREATING METASTATIC PANCREATIC CANCER
- Name des Antragstellers
- Ipsen Biopharm Ltd.
- Name des Einsprechenden
- Sandoz AG
Generics [UK] Limit - Kammer
- 3.3.07
- Leitsatz
- -
- Relevante Rechtsnormen
- European Patent Convention Art 56European Patent Convention Art 87(1)Rules of procedure of the Boards of Appeal 2020 Art 012(6)
- Schlagwörter
- Priority - same invention (no)
Late-filed evidence - should have been submitted in first-instance proceedings (yes)
Late-filed evidence - circumstances of appeal case justify admittance (no)
Inventive step - (yes) - Orientierungssatz
- The Enlarged Board of Appeal determined in G 2/98 that it is a condition for the compliance with the requirement of "the same invention" that the claimed subject-matter is directly and unambiguously derivable from the earlier application. However, the Enlarged Board did not conclude that the requirement of "the same invention" is necessarily satisfied if this condition is fulfilled, irrespective of any technical information associated with the claimed subject-matter, which is only described in the subsequent patent application.
(see point 1.5 of the decision) - Zitierende Akten
- -
Order
For these reasons it is decided that:
The appeals are dismissed.